KR102676629B1 - 암을 치료하는 방법 - Google Patents

암을 치료하는 방법 Download PDF

Info

Publication number
KR102676629B1
KR102676629B1 KR1020177034603A KR20177034603A KR102676629B1 KR 102676629 B1 KR102676629 B1 KR 102676629B1 KR 1020177034603 A KR1020177034603 A KR 1020177034603A KR 20177034603 A KR20177034603 A KR 20177034603A KR 102676629 B1 KR102676629 B1 KR 102676629B1
Authority
KR
South Korea
Prior art keywords
rad1901
treatment
tumor
dose
fulvestrant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177034603A
Other languages
English (en)
Korean (ko)
Other versions
KR20180011780A (ko
Inventor
피오나 가너
개리 해터슬리
Original Assignee
래디어스 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 래디어스 파마슈티컬스, 인코포레이티드 filed Critical 래디어스 파마슈티컬스, 인코포레이티드
Priority to KR1020247019929A priority Critical patent/KR102871380B1/ko
Publication of KR20180011780A publication Critical patent/KR20180011780A/ko
Application granted granted Critical
Publication of KR102676629B1 publication Critical patent/KR102676629B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020177034603A 2015-04-29 2016-04-29 암을 치료하는 방법 Active KR102676629B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247019929A KR102871380B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US201562154699P 2015-04-29 2015-04-29
US62/154,699 2015-04-29
US201562155451P 2015-04-30 2015-04-30
US62/155,451 2015-04-30
US201562158469P 2015-05-07 2015-05-07
US62/158,469 2015-05-07
US201562192940P 2015-07-15 2015-07-15
US201562192944P 2015-07-15 2015-07-15
US62/192,944 2015-07-15
US62/192,940 2015-07-15
US201562252085P 2015-11-06 2015-11-06
US62/252,085 2015-11-06
US201562252916P 2015-11-09 2015-11-09
US62/252,916 2015-11-09
US201562265658P 2015-12-10 2015-12-10
US201562265663P 2015-12-10 2015-12-10
US201562265696P 2015-12-10 2015-12-10
US201562265774P 2015-12-10 2015-12-10
US62/265,774 2015-12-10
US62/265,663 2015-12-10
US62/265,658 2015-12-10
US62/265,696 2015-12-10
US201662323572P 2016-04-15 2016-04-15
US201662323576P 2016-04-15 2016-04-15
US62/323,572 2016-04-15
US62/323,576 2016-04-15
PCT/US2016/030317 WO2016176665A1 (en) 2015-04-29 2016-04-29 Methods of treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247019929A Division KR102871380B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20180011780A KR20180011780A (ko) 2018-02-02
KR102676629B1 true KR102676629B1 (ko) 2024-06-18

Family

ID=57198783

Family Applications (9)

Application Number Title Priority Date Filing Date
KR1020177034603A Active KR102676629B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020247022060A Active KR102871388B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020257033321A Pending KR20250152679A (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020257033320A Pending KR20250153309A (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020247019989A Active KR102871408B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020247019929A Active KR102871380B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020177034606A Active KR102682763B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020257033319A Pending KR20250152678A (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020177034608A Active KR102676705B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법

Family Applications After (8)

Application Number Title Priority Date Filing Date
KR1020247022060A Active KR102871388B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020257033321A Pending KR20250152679A (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020257033320A Pending KR20250153309A (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020247019989A Active KR102871408B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020247019929A Active KR102871380B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020177034606A Active KR102682763B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020257033319A Pending KR20250152678A (ko) 2015-04-29 2016-04-29 암을 치료하는 방법
KR1020177034608A Active KR102676705B1 (ko) 2015-04-29 2016-04-29 암을 치료하는 방법

Country Status (14)

Country Link
US (12) US20180214393A1 (enExample)
EP (4) EP3288383A4 (enExample)
JP (9) JP6926066B2 (enExample)
KR (9) KR102676629B1 (enExample)
CN (5) CN113288887A (enExample)
AU (3) AU2016256469B2 (enExample)
BR (3) BR112017023233A2 (enExample)
CA (3) CA2984357A1 (enExample)
HK (3) HK1251407A1 (enExample)
IL (10) IL297369B2 (enExample)
MX (6) MX384605B (enExample)
RU (3) RU2745678C2 (enExample)
SG (4) SG11201708861VA (enExample)
WO (3) WO2016176665A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
PL3122426T3 (pl) 2014-03-28 2023-05-15 Duke University Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
WO2016176665A1 (en) 2015-04-29 2016-11-03 Radius Health, Inc. Methods of treating cancer
UY37124A (es) 2016-02-15 2017-09-29 Sanofi Sa Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
SG10202104282SA (en) * 2016-09-27 2021-06-29 Radius Pharmaceuticals Inc Methods for treating ovarian cancer
CN112933082A (zh) * 2016-10-11 2021-06-11 杜克大学 Er+乳腺癌的拉索昔芬治疗
RU2742278C2 (ru) 2016-11-17 2021-02-04 Санофи Новые соединения замещенного n-(3-фторпропил)пирролидина, способы их получения и их терапевтическое применение
EP4374925A3 (en) * 2017-01-05 2025-01-15 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
BR112019019261A2 (pt) * 2017-03-16 2020-06-16 Eisai R & D Management Co., Ltd. Terapias de combinação para o tratamento de câncer de mama
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
WO2019097426A1 (en) 2017-11-16 2019-05-23 Novartis Ag Pharmaceutical combination comprising lsz102 and ribociclib
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US10695333B2 (en) 2017-12-01 2020-06-30 Novartis Ag Pharmaceutical combination comprising LSZ102 and alpelisib
US11497730B2 (en) 2018-04-10 2022-11-15 Duke University Lasofoxifene treatment of breast cancer
CN110585429B (zh) * 2018-06-12 2022-10-21 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途
CN112423844B (zh) * 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
TW202026280A (zh) 2018-09-07 2020-07-16 法商賽諾菲公司 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯並[7]輪烯-2-甲酸甲酯的鹽及其製備方法
UA129403C2 (uk) * 2018-11-30 2025-04-16 Радіус Фармасеутікалс, Інк. Елацестрант в комбінації з абемациклібом у жінок з раком молочної залози
PH12021551319A1 (en) * 2018-12-06 2022-05-16 Radius Pharmaceuticals Inc Methods for treating cancer resistant to cdk4/6 inhibitors
MA54393A (fr) * 2018-12-06 2021-10-13 Radius Pharmaceuticals Inc Méthodes de traitement du cancer chez des modèles présentant des mutations esr1
JP7590084B2 (ja) * 2018-12-12 2024-11-26 ケモセントリックス，インコーポレイティド 癌治療のためのｃｘｃｒ７阻害剤
CN119390714A (zh) 2019-02-12 2025-02-07 雷迪厄斯制药公司 方法和化合物
CA3146346A1 (en) * 2019-05-09 2020-11-12 Sanofi 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
KR102341347B1 (ko) * 2019-11-28 2021-12-20 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
CN115175679A (zh) * 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法
IL297216A (en) * 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
EP4149476A1 (en) 2020-05-12 2023-03-22 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
WO2022029799A1 (en) * 2020-08-05 2022-02-10 Aizant Drug Research Solutions Private Limited Solid dosage forms of palbociclib
CA3202592A1 (en) * 2020-12-14 2022-06-23 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
AU2022222660A1 (en) * 2021-02-16 2023-07-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib
CN113662942B (zh) * 2021-08-19 2023-02-07 中国人民解放军陆军军医大学第一附属医院 药物组合物及其在smo突变性髓母细胞瘤中的应用
WO2023064519A1 (en) 2021-10-14 2023-04-20 Teva Pharmaceuticals International Gmbh Solid state forms of elacestrant and processes for preparation thereof
DE102021130035A1 (de) 2021-11-17 2023-05-17 USound GmbH MEMS-Schallwandler mit einer gekrümmten Kontur eines Kragarmelements
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2024104268A1 (zh) * 2022-11-15 2024-05-23 苏州科睿思制药有限公司 艾拉司群二盐酸盐的共晶及其制备方法和用途
KR20240105964A (ko) * 2022-12-29 2024-07-08 주식회사 삼양홀딩스 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법
EP4574811A1 (en) 2023-12-22 2025-06-25 Sandoz Ag Crystalline forms of elacestrant dihydrochloride
WO2025158416A1 (en) 2024-01-25 2025-07-31 Assia Chemical Industries Ltd. Solid state forms of elacestrant and processes for preparation thereof

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
DE19538687A1 (de) 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
DE951551T1 (de) 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2302255C (en) 1997-09-09 2011-11-08 F. Hoffmann-La Roche Ag Fracture healing using pthrp analogs
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
WO1999029364A1 (en) 1997-12-11 1999-06-17 Alza Corporation Device for enhancing transdermal agent flux
EP1037686B1 (en) 1997-12-11 2005-08-17 Alza Corporation Device for enhancing transdermal agent flux
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6091975A (en) 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2001036039A2 (en) 1999-11-17 2001-05-25 Novartis Ag Iontophoretic transdermal delivery of peptides
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20010044431A1 (en) 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU8206401A (en) 2000-08-03 2002-02-18 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
IL154408A0 (en) 2000-08-23 2003-09-17 Akzo Nobel Nv 10-ARYL-11-H BENZO [b] FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
RU2282468C2 (ru) 2000-10-26 2006-08-27 Алза Корпорейшн Устройство для трансдермальной доставки лекарственных средств, имеющее микровыступы с покрытием
CA2444883A1 (en) 2001-04-20 2002-10-31 Alza Corporation Microprojection array having a beneficial agent containing coating
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
US6881203B2 (en) 2001-09-05 2005-04-19 3M Innovative Properties Company Microneedle arrays and methods of manufacturing the same
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
DE60223844T2 (de) 2001-12-20 2008-08-28 Alza Corp., Mountain View Mikrovorsprünge zum durchstechen der haut mit stechtiefensteuerung
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
WO2003068805A2 (en) 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
EP1513547A4 (en) 2002-05-23 2009-11-04 Michael F Holick USE OF PEPTIDE ANALOGUES OF PARATHYROID HORMONE FOR THE TREATMENT OF VAGINAL ATROPHY
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
US7799757B2 (en) 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
MXPA05000597A (es) 2002-07-19 2005-04-28 3M Innovative Properties Co Dispositivos de microaguja y aparatos de administracion por microaguja.
MXPA05003797A (es) 2002-10-14 2005-06-08 Novo Nordisk As Variantes de peptido-2 tipo glucagon.
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
EP1567178A4 (en) 2002-11-01 2009-07-15 Amgen Inc MODULATORS OF RECEPTORS FOR NEUTRAL THERAPY HORMONE AND SIDE-HORSE HORMONE-RELATED PROTEINS
AU2003292625B2 (en) * 2002-12-26 2008-07-24 Eisai R & D Management Co., Ltd. Selective estrogen receptor modulators
EP1654221A2 (en) 2003-06-10 2006-05-10 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
JP2007505164A (ja) 2003-06-10 2007-03-08 スミスクライン ビーチャム コーポレーション アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
KR20060038407A (ko) 2003-06-30 2006-05-03 알자 코포레이션 비휘발성 반대이온을 포함하는 코팅된 미세돌출부용 제제
KR20060029162A (ko) 2003-06-30 2006-04-04 알자 코포레이션 피부 피어싱 미세돌출부를 코팅하는 방법
WO2005014034A1 (en) 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
US7141544B2 (en) 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
BRPI0415967A (pt) 2003-10-28 2007-01-23 Alza Corp aplicação de conjugados de polìmero de peptìdeos e proteìnas terapêuticos através de microprojeções revestidas
KR20060099523A (ko) 2003-10-31 2006-09-19 알자 코포레이션 미세 돌출부 어레이를 위한 자가 작동 어플리케이터
AU2004292954A1 (en) 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
US20070129409A1 (en) 2003-11-20 2007-06-07 Lain-Yen Hu Androgen receptor modulators
KR20070011252A (ko) 2003-11-21 2007-01-24 알자 코포레이션 초음파 보조 경피 백신전달방법 및 시스템
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
WO2005066194A1 (en) 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
CA2562132A1 (en) 2004-04-08 2005-10-27 Merck & Co., Inc. 17 beta-acetamide-4-azasteroids as androgen receptor modulators
CA2567056A1 (en) 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
MXPA06013115A (es) 2004-05-11 2007-02-28 Pfizer Prod Inc Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
EP1765406A4 (en) 2004-05-21 2012-11-28 Mediplex Corp ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS
US20090069226A1 (en) 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
AU2005310238A1 (en) 2004-10-29 2006-06-08 Merck Sharp & Dohme Corp. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
CN101102809B (zh) 2004-11-18 2010-05-26 3M创新有限公司 涂敷微针阵列的遮蔽方法
JP2008520331A (ja) 2004-11-18 2008-06-19 トランスファーマ メディカル リミテッド 薬剤の経皮的送達のためのマイクロチャネル形成とイオントフォレーシスの組合せ
US20060188555A1 (en) 2005-01-21 2006-08-24 Micheal Cormier Therapeutic peptide formulations with improved stability
WO2006113552A2 (en) 2005-04-15 2006-10-26 Smithkline Beecham Corporation Cyanoarylamines
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
WO2006133216A2 (en) 2005-06-06 2006-12-14 Smithkline Beecham Corporation 4-substituted arylamine derivatives and their use in pharmaceutical compositions
US20090227571A1 (en) 2005-07-01 2009-09-10 Ligand Pharmaceuticals Incorporated Androgen Receptor Modulator Compounds and Methods
US20070021216A1 (en) 2005-07-19 2007-01-25 Sony Ericsson Mobile Communications Ab Seamless gaming method and apparatus
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
WO2007061781A1 (en) 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
ES2551305T3 (es) 2005-12-28 2015-11-17 Alza Corporation Formulaciones terapéuticas estables
CA2680690A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
EP2024078A2 (en) 2006-04-20 2009-02-18 Velocys, Inc. Process for treating and/or forming a non-newtonian fluid using microchannel process technology
EA200802166A1 (ru) 2006-04-20 2009-06-30 Эмджен Инк. Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
CN101085743B (zh) 2006-06-06 2012-02-15 浙江大德药业集团有限公司 含氟烷氧基康普立停衍生物及制法和用途
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
WO2008008433A2 (en) 2006-07-12 2008-01-17 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
CN101528214B (zh) 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
EA015644B1 (ru) 2006-08-25 2011-10-31 Арес Трейдинг С.А. Способ лечения заболеваний хряща
CN1927815A (zh) 2006-09-25 2007-03-14 天津理工大学 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
SI2957278T1 (sl) 2006-10-03 2017-09-29 Radius Health, Inc. Stabilni sestavek, ki obsega PTHrP, in njegova uporaba
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
ES2473620T3 (es) 2007-02-06 2014-07-07 Hisamitsu Pharmaceutical Co., Inc. Dispositivo de microagujas para el diagnóstico de una alergia
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
WO2008130587A2 (en) 2007-04-16 2008-10-30 Corium International, Inc. Solvent-cast microneedle arrays containing active
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
WO2008145125A1 (en) * 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
US20110009387A1 (en) 2007-06-12 2011-01-13 Andrea Dawn Basso-Porcaro Histone h2ax (hh2ax) biomarker for fti sensitivity
US8450481B2 (en) 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US20120150023A1 (en) 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
ES2612061T3 (es) 2007-09-28 2017-05-11 The Queen's University Of Belfast Dispositivo y método de suministro
US20090117158A1 (en) 2007-10-23 2009-05-07 Mahmoud Ameri Transdermal sustained release drug delivery
EP2052736A1 (en) 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
WO2009065126A2 (en) 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
WO2009137104A1 (en) * 2008-05-09 2009-11-12 Radius Health, Inc. Combination therapy for breastcancer comprising an antiestrogenic agent
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
EP2349200A1 (en) 2008-10-15 2011-08-03 Intarcia Therapeutics, Inc Highly concentrated drug particles, formulations, suspensions and uses thereof
KR101668502B1 (ko) 2008-11-04 2016-10-21 아스카 세이야쿠 가부시키가이샤 난포자극호르몬 함유 수성 조성물
EP2355887B1 (en) 2008-11-18 2017-08-02 3M Innovative Properties Company Hollow microneedle array
JP5902390B2 (ja) 2008-12-26 2016-04-13 久光製薬株式会社 マイクロニードルデバイス
US20100203014A1 (en) 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
US20110006458A1 (en) 2009-04-24 2011-01-13 Corium International, Inc. Methods for manufacturing microprojection arrays
JP5702384B2 (ja) 2009-07-31 2015-04-15 スリーエム イノベイティブ プロパティズ カンパニー 中空マイクロニードルアレイ
EP2496262A2 (en) 2009-11-02 2012-09-12 Université de Genève Stabilized protein formulations and use thereof
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
CN101912600B (zh) 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
EP2566501B1 (en) 2010-05-04 2019-03-13 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
EP2575845B1 (en) 2010-05-28 2017-02-15 3M Innovative Properties Company Aqueous formulations for coating microneedle arrays
KR20140089402A (ko) * 2010-06-16 2014-07-14 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
AU2012223279A1 (en) 2011-03-01 2013-09-26 Sloan-Kettering Institute For Cancer Research Parathyroid hormone analogs, compositions and uses thereof
JP6033280B2 (ja) 2011-04-22 2016-11-30 ラジウス ヘルス，インコーポレイテッド ＰＴＨ、ＰＴＨｒＰ、および関連ペプチドの薬剤送達方法
WO2013082418A1 (en) 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
GB201217439D0 (en) 2012-09-28 2012-11-14 Topotarget As Combination therapy
WO2014203129A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
MX2015016171A (es) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
CN104436194B (zh) 2013-09-18 2018-03-30 北京大学 具有协同增效作用的抗癌组合物
EP3099305B1 (en) * 2014-01-27 2025-11-19 Dna Seq 2, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
PL3122426T3 (pl) * 2014-03-28 2023-05-15 Duke University Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
EP3233828B1 (en) 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Estrogen receptor modulators and uses thereof
AR104068A1 (es) * 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
WO2016176665A1 (en) 2015-04-29 2016-11-03 Radius Health, Inc. Methods of treating cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Breast Cancer Research, 16(494), 1-8쪽(2014.) 1부.*
인터넷 뉴스(globeNewswire, FDA Accepts IND Application for Radius Health's Investigational Drug RAD1901 Being Developed for Potential Use in Metastatic Breast Cancer, 2014.12.19.) 1부.*

Also Published As

Publication number Publication date
RU2017140674A (ru) 2019-05-29
IL297369B1 (en) 2024-02-01
HK1251409A1 (zh) 2019-02-01
CN113750091B (zh) 2025-03-11
IL255148B2 (en) 2023-04-01
MX2017013794A (es) 2018-08-15
US20240091177A1 (en) 2024-03-21
SG11201708858WA (en) 2017-11-29
KR20180011780A (ko) 2018-02-02
CN113750091A (zh) 2021-12-07
MX2021004881A (es) 2021-07-21
US20220110890A1 (en) 2022-04-14
JP6926065B2 (ja) 2021-08-25
RU2017140676A (ru) 2019-05-29
CA2984195C (en) 2023-10-24
WO2016176666A1 (en) 2016-11-03
AU2016256469A8 (en) 2017-12-21
US20200368183A1 (en) 2020-11-26
EP3288382A1 (en) 2018-03-07
EP4039253A1 (en) 2022-08-10
IL255148A0 (en) 2017-12-31
IL307981B1 (en) 2025-11-01
JP2024120996A (ja) 2024-09-05
AU2016256470B2 (en) 2020-10-15
JP7262508B2 (ja) 2023-04-21
RU2737496C2 (ru) 2020-12-01
IL297369B2 (en) 2024-06-01
SG10202104177VA (en) 2021-05-28
IL323926A (en) 2025-12-01
US20180169101A1 (en) 2018-06-21
IL255189B1 (en) 2023-12-01
JP7019422B2 (ja) 2022-02-15
IL297369A (en) 2022-12-01
RU2017140675A3 (enExample) 2019-09-27
RU2017140674A3 (enExample) 2019-09-27
AU2016256471B2 (en) 2020-09-10
SG11201708861VA (en) 2017-11-29
JP2025170141A (ja) 2025-11-14
IL307983A (en) 2023-12-01
MX393599B (es) 2025-03-19
IL255261B2 (en) 2024-03-01
CA2984200A1 (en) 2016-11-03
CA2984357A1 (en) 2016-11-03
BR112017023228A2 (en) 2018-11-06
IL255148B (en) 2022-12-01
IL255261A0 (en) 2017-12-31
US20180153828A1 (en) 2018-06-07
MX2017013801A (es) 2018-08-15
MX384908B (es) 2025-03-14
US20200046655A1 (en) 2020-02-13
CN108135177B (zh) 2021-06-01
CN113288887A (zh) 2021-08-24
NZ737825A (en) 2024-10-25
MX384605B (es) 2025-03-14
IL323924A (en) 2025-12-01
JP7516472B2 (ja) 2024-07-16
KR20240095372A (ko) 2024-06-25
KR20250152678A (ko) 2025-10-23
JP7146992B2 (ja) 2022-10-04
KR20180042155A (ko) 2018-04-25
CN108024540B (zh) 2021-09-17
KR102871408B1 (ko) 2025-10-14
BR112017023269A2 (en) 2018-11-06
US20250367140A1 (en) 2025-12-04
JP2018514593A (ja) 2018-06-07
HK1251408A1 (zh) 2019-02-01
JP7745708B2 (ja) 2025-09-29
EP3294065A1 (en) 2018-03-21
KR102871380B1 (ko) 2025-10-14
CN108024540A (zh) 2018-05-11
EP3288383A4 (en) 2019-01-23
KR20180043202A (ko) 2018-04-27
IL255261B1 (en) 2023-11-01
JP2023052631A (ja) 2023-04-11
RU2017140676A3 (enExample) 2019-09-27
US12263141B2 (en) 2025-04-01
JP2021105064A (ja) 2021-07-26
US20180214393A1 (en) 2018-08-02
WO2016176665A1 (en) 2016-11-03
JP2021102640A (ja) 2021-07-15
EP3288383A1 (en) 2018-03-07
IL310069B1 (en) 2025-04-01
RU2747228C2 (ru) 2021-04-29
KR20240097966A (ko) 2024-06-27
IL307983B1 (en) 2025-11-01
AU2016256470A1 (en) 2017-12-14
RU2745678C2 (ru) 2021-03-30
US20240099996A1 (en) 2024-03-28
MX2021003389A (es) 2021-05-28
KR20250153309A (ko) 2025-10-24
RU2017140675A (ru) 2019-05-29
IL310069A (en) 2024-03-01
KR20250152679A (ko) 2025-10-23
US20250367141A1 (en) 2025-12-04
JP6926066B2 (ja) 2021-08-25
CN108135177A (zh) 2018-06-08
BR112017023233A2 (en) 2018-11-06
US20220339126A1 (en) 2022-10-27
CA2984200C (en) 2024-03-19
AU2016256471A1 (en) 2017-12-21
US11819480B2 (en) 2023-11-21
CN108024541B (zh) 2021-07-20
JP2022172039A (ja) 2022-11-14
IL255189B2 (en) 2024-04-01
JP2018518529A (ja) 2018-07-12
MX394676B (es) 2025-03-24
NZ737822A (en) 2024-10-25
KR102682763B1 (ko) 2024-07-05
JP7696378B2 (ja) 2025-06-20
CN108024541A (zh) 2018-05-11
NZ737819A (en) 2024-10-25
WO2016176664A1 (en) 2016-11-03
KR102871388B1 (ko) 2025-10-14
IL307981A (en) 2023-12-01
HK1251407A1 (zh) 2019-02-01
AU2016256469A1 (en) 2017-12-14
IL319266A (en) 2025-04-01
AU2016256469B2 (en) 2020-12-10
JP2018514549A (ja) 2018-06-07
MX2017013802A (es) 2018-08-15
US20200038343A1 (en) 2020-02-06
KR20240110098A (ko) 2024-07-12
IL255189A0 (en) 2017-12-31
MX2021005561A (es) 2022-07-01
KR102676705B1 (ko) 2024-06-18
US11413258B2 (en) 2022-08-16
EP3288382A4 (en) 2019-01-30
EP3294065A4 (en) 2019-03-20
IL310069B2 (en) 2025-08-01
CA2984195A1 (en) 2016-11-03
SG11201708860SA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
KR102676629B1 (ko) 암을 치료하는 방법
HK40079056A (en) Methods of treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210426

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230522

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231120

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230522

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20231120

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230719

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210426

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240314

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20240220

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20231120

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20230719

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210426

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240614

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240614

End annual number: 3

Start annual number: 1

PG1601 Publication of registration